Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma

Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma

Primary liver cancer (PLC) is the first leading cause of immature cancer death in China. Hepatocellular carcinoma (HCC) in China accounts for 93.0% of PLC. Chronic infection with hepatitis B virus (HBV) HCC contributes to 84.4% of HCC. During HBV-induced hepatocarcinogenesis, non-resolving inflammat...

Full description

Bibliographic Details
Main Author: CAO Guangwen
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2022-08-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
hepatitis b virus
hepatocellular carcinoma
tumor microenvironment
mutation
targeted therapy
immunotherapy
Online Access:http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0377

Similar Items

Similar Items